A Phase III Randomized, Double-Blind Study Of SU011248 (Sunitinib, SUTENT), A Oral Novel Multitargeted Tyrosine Kinase Inhibitor, Given Daily As A Continuous Dose Versus Placebo In Patients With Advanced/Metastatic Neuroendocrine Tumours Of The Digestive Tract.

Trial Profile

A Phase III Randomized, Double-Blind Study Of SU011248 (Sunitinib, SUTENT), A Oral Novel Multitargeted Tyrosine Kinase Inhibitor, Given Daily As A Continuous Dose Versus Placebo In Patients With Advanced/Metastatic Neuroendocrine Tumours Of The Digestive Tract.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Neuroendocrine carcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Dec 2016 Results (n=144) assessing patient-reported outcomes and quality of life, published in the Targeted Oncology
    • 02 Oct 2012 Updated overall survival analysis presented at the 37th Congress of the European Society for Medical Oncology.
    • 04 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top